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Abstract
PURPOSE: Angiopoietins and their receptor, Tie2, participate in angiogenesis, regulation of vascular permeability, and
inflammation, all central to the pathogenesis of malignant pleural effusions (MPEs). In the present study, we aimed
to examine the role of the angiopoietin/Tie2 axis in MPE pathogenesis. EXPERIMENTAL DESIGN: MPE was induced
by intrapleural injection of murine adenocarcinoma cells in C57BL/6 mice. Animals were given twice-weekly intra-
peritoneal injections of 40 mg/kg MuTekdeltaFc or vehicle. MuTekdeltaFc is a soluble Tie2 (sTie2) receptor that binds
murine angiopoietins thereby disrupting their interaction with Tie2 receptors expressed on tissues. Animals were
killed on day 14. RESULTS: Angiopoietin/Tie2 axis blockade significantly reduced pleural fluid volume and pleural tumor
foci. The mean ± SEM pleural fluid volumes were 617 ± 48 μl and 316 ± 62 μl for the control and treated groups,
respectively (P = .001), whereas the mean ± SEM tumor foci were 7.3 ± 1.0 and 3.0 ± 0.52 for the control and
treated groups, respectively (P = .001). In addition, tumor-associated cachexia, tumor angiogenesis, pleural vascular
permeability, recruitment of inflammatory cells to the pleural cavity, and local elaboration of vascular endothelial
growth factor and interleukin 6 were also downregulated, and tumor cell apoptosis was induced in animals treated
with the inhibitor. CONCLUSIONS: Our results indicate that the angiopoietin/Tie2 axis is an important component of
MPE pathogenesis. Further studies are required to determine whether therapeutic interventions targeting this pathway
could be beneficial for patients with MPE.
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Introduction
Malignant pleural effusion (MPE) is a common condition, affecting
∼660 patients per million population each year and is associated with
a very short survival and poor quality of life [1–3]. Current therapies
used to prevent the reaccumulation of pleural fluid and relieve symp-
toms include pleurodesis (chemical-induced pleural fibrosis aiming
at eliminating the pleural space), indwelling pleural catheters, and
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chemotherapy. All these are of variable efficacy and may cause seri-
ous adverse effects [1,4]. Nevertheless, very little is known about its
pathogenesis. Unmasking the mechanisms of the disease would hope-
fully permit the development of more specific, effective, and safer
treatment modalities.
Angiogenesis, pleural vascular hyperpermeability, and inflamma-
tion are considered central to the pathogenesis of MPE [3,5–8]. An-
giopoietins 1 to 4 are important regulators of angiogenesis and exert
their actions through binding a common tyrosine kinase receptor
(Tie2) that is mainly expressed on the surface of endothelial cells
[9]. An emerging body of evidence supports a central role for the
angiopoietin/Tie2 pathway in tumor-associated angiogenesis [9,10]
as well as in regulation of vascular permeability and inflammation
[9,11–15], all central to the pathogenesis of MPE. We have previously
reported that pleural expression of angiopoietin 2 is increased in pa-
tients with exudative pleural effusions, including MPE [16]. How-
ever, the role of angiopoietin/Tie2 signaling in the pathogenesis of
MPE has not been examined. The aim of the present study was to de-
termine the functional significance of the angiopoietin/Tie2 pathway
in MPE formation using a recently developed model of MPE [6]. To
interfere with angiopoietin/Tie2 axis signaling, we used MuTekdeltaFc,
a sTie2 receptor that binds murine angiopoietins and prevents their
interaction with Tie2 receptors expressed on tissues. We hypothesized
that systemic administration of sTie2 would impair tumor angiogenesis
and downregulate pleural inflammation and pleural vascular permeabil-
ity, thereby inhibiting pleural tumor growth and pleural fluid accumu-
lation that occur after intrapleural injection of cancer cells in mice.
Materials and Methods
In Vivo Studies
C57BL/6 mice (Hellenic Pasteur Institute, Athens, Greece) were
inbred at the General Hospital “Evangelismos” (Athens, Greece). Ex-
periments were approved by the Veterinary Administration Bureau,
Prefecture of Athens, Greece. Intrapleural injections with mouse
Lewis lung adenocarcinoma (LLC; ATCC, Manassas, VA) and sacri-
fice (14 days after LLC injection) were performed as described pre-
viously [6–8]. Starting 3 days after intrapleural injection of LLC cells,
animals were given twice-weekly intraperitoneal injections of 40 mg/kg
MuTekdeltaFc (Amgen, Inc., Thousand Oaks, CA), a murine sTie2,
or vehicle (injection volume = 50 μl), for a total of four doses. Four-
teen days after tumor cell injection, mice were killed by CO2 for pleu-
ral fluid and tumor collection, as described previously [6–8].
Pleural Tumor Enumeration and Processing
Pleural tumor nodules were enumerated by three independent and
blinded readers under a dissecting microscope, and the average num-
ber was used for analyses. Pleural tumors were dissected avoiding ad-
jacent normal tissue, snap-frozen in liquid nitrogen, and stored at
−80°C. Tumor tissue was suspended in protein extraction buffer con-
taining protease inhibitors (volume = 1 ml), and cytoplasmic protein
extracts were collected after Dounce homogenization and centrifuga-
tion (16,000g for 5 minutes), as described previously [7,8]. All mea-
surements in tumor cytoplasmic protein extracts were normalized for
protein content.
In Vivo Vascular Permeability Assays
To determine pleural vascular permeability in mice bearing MPEs,
the animals received 200 μl of 4 mg/ml Evans’ blue (total dose =
0.8 mg) i.v. on day 14 after LLC cell injection and were killed 1 hour
later. Pleural fluid Evans’ blue levels were determined by measuring
absorbance at 630 nm in comparison to standards of known Evans’
blue concentrations [6–8]. To evaluate the vascular permeability–
enhancing properties of angiopoietins contained in pleural fluid,
we used a modified Miles vascular permeability assay [7]. Malignant
pleural effusion supernatants from untreated mice or PBS (volume =
50 μl) were injected at different spots of the shaved dorsal skin of
C57B/6 mice. sTie2 (MuTekdeltaFc) was used to antagonize the effect
of angiopoietins. Anti–vascular endothelial growth factor (VEGF)–
neutralizing antibodies were used to abrogate the effect of VEGF, a
factor with an established role in MPE-associated vascular hyperperme-
ability [5]. More specifically, five spots on each mouse received 1) PBS,
2) premixed MPE + PBS, 3) premixed MPE + 10 ng of sTie2, 4) pre-
mixed MPE + 400 ng of neutralizing anti-VEGF antibody (R&D sys-
tems, Abingdon, UK), or 5) premixed MPE + 10 ng of sTie2 + 400 ng
of neutralizing anti-VEGF antibody. The mice received 200 μl of
4 mg/ml Evans’ blue (total dose = 0.8 mg) i.v. immediately after der-
mal injections and were killed 30 minutes later. The skin was removed,
the test sites were photographed, and the area of Evans’ blue extra-
vasation was determined using ImageJ freeware (Rasband 1997-2006,
available at http://rsb.info.nih.gov/ij).
Cytology-Histology
Nucleated pleural fluid cells count was assessed using a Neubauer
hematocytometer. Cytocentrifugal specimens (cytospins) were pre-
pared and stained with May-Gruenwald-Giemsa as described else-
where [6,7]. Pleural tumor tissues were fixed in neutral-buffered
formalin for 24 hours and 70% ethanol for 3 days, sectioned (thick-
ness = 5 μm), and stained with hematoxylin and eosin or immuno-
labeled for proliferating cell nuclear antigen (PCNA; Santa Cruz
Biotechnology, Santa Cruz, CA), terminal deoxynucleotidyl nick-end
labeling (TUNEL; Roche, Penzberg, Germany), or factor VIII–related
antigen (Invitrogen, San Francisco, CA), as described previously [7,8].
Quantification of immunoreactivity has been described elsewhere
[17,18]. Factor VIII–related antigen labeling was quantified by the
“hotspot” method [19]. Briefly, the whole tumor area was scanned
at low power (A°, 40) to detect areas of enhanced angiogenesis (hot-
spots). Subsequently, five different, nonoverlapping, high-power fields
(A°, 600) within hotspots from each tumor were assessed by two
blinded readers for the number of individual cells or clusters of cells
(counted as a unit) exhibiting immunoreactivity. Results were averaged
for each tumor and then for each mouse.
Biochemical and Cytokine Determinations
Pleural fluid and cell supernatant protein content was determined
using the Bio-Rad protein assay (Hercules, CA). Mouse VEGF, tumor
necrosis factor α (TNF-α), and interleukin 6 (IL-6) were determined
using ELISA (Peprotech EC, London, UK, for VEGF; R&D Systems
for TNF-α and IL-6). The minimum detectable levels were 31.3, 5.1,
and 1.6 pg/ml for VEGF, TNF-α, and IL-6, respectively.
In Vitro Cell Viability Assay
Lewis lung adenocarcinoma cells were plated at equal densities in
96-well culture dishes and treatment with sTie2 (10, 30, and 100 μg/
ml) was started when cells were ∼30% confluent. Cell viability was
assessed after 4, 24, and 48 hours by a 3-(4,5-dimethylthiazol-2-yl)-
5-(3-carboxymethoxyphenyl)-2-(4-sulphophenyl)-2H -tetrazolium
inner salt (MTS) reduction assay (Promega, Madison, WI).
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Statistical Analysis
Data are presented as mean ± SE. To assess the difference in the
means between different groups, unpaired and paired Student’s t-tests
and one-way analysis of variance with least squared difference post hoc
tests were used, as appropriate. All P values are 2-tailed; P < .05 were
considered significant. Statistical analyses were done using SPSS v.13.0.0
(SPSS, Inc., Chicago, IL).
Results
sTie2 Inhibits Intrapleural Tumor Dissemination, Pleural
Fluid Accumulation, and Tumor-Associated Cachexia
We initially examined the effects of angiopoietin/Tie2 signaling
blockade on macroscopic parameters of MPE induced by intrapleural
injection of adenocarcinoma cells. The primary end points were the
volume of pleural fluid and the number of pleural tumors. The sTie2-
treated animals had significantly less pleural fluid (Figure 1A) and fewer
pleural tumor implantations (Figure 1B) compared with the controls.
In particular, the mean ± SEM pleural fluid volume was 617 ± 48 μl
for the control and 316 ± 62 μl for the treated group (P = .001), whereas
tumor foci were 7.3 ± 1 and 3.0 ± 0.52 for the control and treated
groups, respectively (P = .001). In addition, whereas at the beginning
of the experiment, body weight did not differ significantly between
groups (P = .24), on the day of sacrifice, the animals in the treatment
group lost 0.23 ± 0.54 g, which was significantly less (P = .03) than the
animals in the control group, 1.95 ± 0.54 g (Figure 1C ). These data
clearly indicate that the angiopoietin signal transduction pathway pro-
motes MPE formation by lung adenocarcinoma cells.
sTie2 Limits Tumor Angiogenesis and Pleural
Vascular Hyperpermeability
We next studied the effect of sTie2 on tumor angiogenesis and
pleural vascular hyperpermeability, both central to the excessive pleural
fluid production and the resultant formation of a MPE [5–7]. Tumor
angiogenesis, assessed by tumor tissue immunostaining using an anti–
factor VIII–related antigen antibody (fVIIIra), was found to be sig-
nificantly suppressed. The mean ± SEM numbers of fVIIIra-positive
clusters per high-power field were 2.9 ± 0.27 for the animals treated
with the inhibitor compared with 11.7 ± 1.19 (P < .001) in those
treated with the control solution (Figure 2A). For quantification of
pleural vascular hyperpermeability, control and sTie2-treated mice re-
ceived 0.8 mg of Evans’ blue (an albumin-binding dye) i.v. 1 hour be-
fore sacrifice [7]. The total mean ± SEM pleural fluid level of Evan’s
blue, a marker of pleural vascular plasma leakage, was 28 ± 3 μg in
treated animals, which was significantly lower than that in the control
animals, 69 ± 10 μg (P = .003). This indicates that sTie2 limits pleural
vascular permeability associated with the growth of the tumor cells in
the pleural cavity (Figure 2B).
To evaluate the contribution of angiopoietins in the induction of
MPE-associated vascular permeability, we performed a modified Mile’s
assay injecting pleural fluid supernatants from control animals pre-
treated with PBS, sTie2 or/and anti-VEGF neutralizing antibody into
the skin of mice previously administered Evan’s blue i.v. and measured
the area of the dermal dye extravasation. As shown in Figure 2, C and
D, both sTie2 and anti-VEGF significantly (P < .001) reduced MPE-
induced skin vascular permeability. Interestingly, the inhibition of
MPE-induced vascular permeability conferred by combination of
sTie2 and anti-VEGF was significantly greater (P < .05) than that
caused by anti-VEGF alone. In accord with our hypothesis, these re-
sults show that the angiopoietin/Tie2 axis enhances new vessel for-
mation and vascular leakiness associated with MPE pathogenesis.
sTie2 Suppresses Pleural Inflammation Associated with
MPE Formation
In addition to the effects on plasma leakage in the pleural cavity,
angiopoietin/Tie2 axis blockade resulted in significant down-regulation
of malignancy-associated pleural inflammation. Treatment with the
inhibitor resulted in a significant reduction of pleural fluid inflamma-
tory cells (P = .003), including mononuclear cells (P = .038), lympho-
cytes (P = .002), and neutrophils (P = .001; Figure 3A). We further
examined whether sTie2 treatment affects local elaboration of the
proinflammatory and angiogenic mediators, VEGF, IL-6, and TNF-α,
because all of the above have been previously shown to promote MPE
through induction of angiogenesis and enhancement of pleural vascular
permeability [5–8,20]. The pleural fluid levels of VEGF and IL-6 were
significantly decreased in the treated group (Figure 3, B–D). In contrast
the tumor levels of VEGF, TNF-α, or IL-6 did not differ significantly
between the treated and control groups (Figure 3, B–D). These data
suggest that angiopoietin signaling promotes proinflammatory and an-
giogenic mediator expression in MPE.
Figure 1. sTie2 treatment inhibits pleural fluid accumulation, intrapleural tumor dissemination, and tumor-associated cachexia. sTie2-
treated animals had significantly less pleural fluid (A) and pleural tumor implantations (B). In addition, treatment with the inhibitor resulted
in reduced weight loss compared to controls (C). Columns, points indicate mean; bars, SEM; P, probability value; n, sample size; ns,
not significant.
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sTie2 Induces Tumor Cell Apoptosis In Vivo
Tumor cell proliferation in vivo assessed by PCNA immunolabel-
ing of pleural tumor tissue was not impaired by sTie2 treatment (Fig-
ure 4A). In contrast, in vivo tumor cell apoptosis assessed by TUNEL
was significantly increased by sTie2 treatment (Figure 4B). The mean
± SEM TUNEL-positive cells per high-power field were 19 ± 2.8 in
sTie2-treated animals and 7.8 ± 1 in the control animals (P < .001).
In vitro, treatment of LLC cells with sTie2 for 24 and 48 hours have no
effect on tumor cell viability assessed by MTS assay (data not shown).
Discussion
In this study, we assessed whether angiopoietin/Tie2 signaling par-
ticipates in the pathogenesis of MPE. We postulated that the sys-
temic administration of a compound that prevents the interaction
of the angiopoietins with their receptor would reduce MPE formation
in mice. This proved to be the case: inhibition of the angiopoietin/
Tie2 axis suppressed pleural fluid accumulation, impaired tumor dis-
semination in the pleural cavity, and halted tumor-induced cachexia.
These effects were linked to the attenuation of pleural inflammation, re-
duction of VEGF and IL-6 local release, partial inhibition of malignancy-
associated tumor angiogenesis, and pleural vascular hyperpermeability
as well as induction of tumor cell apoptosis.
Malignant pleural effusion develops mostly as a result of increased
pleural fluid production, which, in turn, is secondary to mutually
dependent biological phenomena including an ongoing angiogenic
process and the associated enhanced vascular permeability and pleu-
ral inflammation [3,5–8,20]. The present study demonstrates that
angiopoietin/Tie2 axis blockage impairs new vessel formation in the
tumor, attenuates pleural vascular leakage and decreases recruitment of
inflammatory cells. More interestingly, a Miles assay in the mouse skin
disclosed that the propermeability effects mediated by angiopoietin/
Tie2 signaling are independent and complementary to that exerted
by VEGF. The above observations are in concert with the established
role of the axis in the regulation of angiogenesis, vascular permeability,
and inflammation [9,10,12–15]. In this regard, angiopoietins, along
with VEGF, are central to the regulation of tumor angiogenesis [10].
It is classically considered that angiopoietin 2 overexpression in the
tumor microenvironment destabilizes the existing vasculature to allow
microvessel formation from the surrounding host vessels, whereas
angiopoietin 1 acts as a maturation and stabilization signal [9]. Strict
temporal regulation of angiopoietin expression is required for tumor
angiogenesis to be accomplished because sustained angiopoietin 2 ex-
pression disrupts vessel formation and inhibits tumor growth [21].
However, the exact role of individual angiopoietin family members
Figure 2. sTie2 treatment suppresses pleural tumor angiogenesis and vascular hyperpermeability in the pleura and the skin. (A) sTie2-
treated animals were characterized by reduced pleural tumor angiogenesis as assessed by immune-labeling of fVIIIra. (B) Determination
of pleural fluid levels of albumin-binding Evans’ blue after i.v. injection of the dye demonstrated that sTie2-treated mice were charac-
terized by markedly reduced vascular leakiness of albumin compared with the controls. (C) Seven C57B/6 mice received intradermal
injections of PBS (negative control) or cell-free MPE fluid with or without sTie2 and/or anti-VEGF neutralizing antibody at different spots
of the shaved dorsal skin. Inverted dermis of representative mouse with test sites in dashed circles. (D) Summary of data obtained from
experiment described under (C). sTie2 reduced the vascular leakage induced by MPE fluid and had an additive effect on the reduction of
permeability caused by VEGF neutralization (**P< .01 and ***P< .001 compared with PBS; ###P< .001 compared with MPE; §P< .05
compared with MPE + anti-VEGF). Columns indicate mean; bars, SEM; P, probability values; n, sample size.
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is still controversial [22]. In addition, angiopoietin 2 increases vascular
permeability of the existing vasculature [15], an effect that, along with
the leakage from newly formed, yet immature microvessels, contrib-
utes to fluid exudation in tumor and surrounding tissues, including
the pleural cavity. We believe that the robust antiangiogenic [23,24]
and antipermeability [15] properties of sTie2 explain for the most part
the MPE-inhibiting effect of the compound in our system. Interestingly,
enhanced tumor cell apoptosis was observed in treated animals albeit
in vitro cell viability was not affected by sTie2, suggesting that the in-
hibitor blocks a survival-promoting event that exclusively occurs in vivo.
Hence, most likely tumor cell apoptosis is secondary to tissue hypoxia,
which results from impairment of tumor angiogenesis. One could thus
propose thatMPE-limiting effects of sTie2 are secondary to the reduction
of pleural tumor burden. However, the observation that pretreatment of
pleural fluid from control mice with sTie2 reduced MPE-induced vascu-
lar permeability, and given the central role of vascular leakage in MPE
pathobiology, it is reasonable to assume that the compound exerts a direct
inhibitory effect in pleural fluid accumulation. From a clinical perspec-
tive, we believe that the ideal treatment of patients with MPE should
target both pleural fluid production and the tumor per se.
Along with their role in angiogenesis, angiopoietins have been re-
cently implicated in the regulation of inflammation, an increasingly
recognized factor in the pathogenesis of MPE [6–8]. Although angio-
poietin 1 was initially reported as an anti-inflammatory factor [25,26],
it was subsequently shown that it may augment adhesion onto endo-
thelial cells and chemotaxis of Tie2-expressing neutrophils [11,12].
Similarly, angiopoietin 2 was shown to promote neutrophil recruit-
ment at sites of acute inflammation [11–13] and to induce local in-
flammation and plasma leakage when injected in mouse paw [15].
More interestingly, Tie2 is also expressed by and mediates the angio-
poietin 2–induced recruitment of a subset of blood monocytes with po-
tent angiogenic properties at the tumor microenvironment [14,27–29].
We recently were able to study MPE-associated pleural inflammation
using a novel model of the disease in immunocompetent mice that
permits the development of a host antitumor immune response [6–8].
Using this model, we demonstrate in the present study that the influx
of inflammatory cells in the pleural cavity and the pleural fluid concen-
trations of VEGF and IL-6 were remarkably decreased in sTie2-treated
animals with MPE. Interestingly, the inhibitor did not impair VEGF
and IL-6 expression by the tumor. It is thus reasonable to speculate that
Figure 4. sTie2 treatment enhances tumor cell apoptosis in vivo.
Pleural tumor tissue from control and sTie2 treated as evaluated for
PCNA (A) and TUNEL (B) immunoreactivity. sTie2 treatment did not
affect tumor cell proliferation in vivo but significantly increased tumor
cell apoptosis Columns indicate mean; bars, SEM; P, probability
values; n, sample size.
Figure 3. sTie2 downregulated the expression of proangiogenic
and proinflammatory mediators in the tumor microenvironment.
(A) Nucleated and differential cell counts from control and sTie2-
treated mice. (B) Vascular endothelial growth factor levels in MPE
and serum from mice treated as in Figure 1 (n = 8 per data point).
(C) Interleukin 6 levels in MPE and serum from mice treated as
in Figure 1 (n = 8 per data point). Columns indicate mean; bars,
SEM; P, probability values; ns, not significant.
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a significant portion of VEGF and IL-6, both important for MPE for-
mation [5,20], comes from the inflammatory cells invading the pleural
space. From the data presented above, it follows that sTie2 treatment
might affect tumor angiogenesis and pleural vascular permeability not
only directly, that is, by intervening on the Tie2 signaling in endothelial
cells, but also indirectly, through a potent inhibitory effect on MPE-
associated inflammatory response.
Whereas the present study demonstrates a potent antiangiogenic,
antipermeability, and anti-inflammatory effect of sTie2 in mice with
MPE, it is limited by the fact that it does not reveal the exact molecu-
lar events influenced by the compound. Because LLC cells are known
to express both angiopoietins 1 (although weakly) and 2, this difficulty
is inherent to the nonselective nature of sTie2 that binds all members
of the angiopoietin family [30]. More intriguingly, different angio-
poietins interact with the naturally occurring receptor to mediate com-
plementary and often opposing effects [9,10]. Accordingly, whereas
angiopoietins 1, 3, and 4 elicit Tie2 phosphorylation (activation),
angiopoietin 2 may act both as a Tie2 agonist and as an antagonist de-
pending on the cellular context [10,31–36]. The agent used in the pres-
ent study prevents both angiopoietins 1 and 2 binding to their receptor
and abolishes Tie2 phosphorylation on endothelial cells [9,37]. The last
action can partly explain our findings because Tie2 activation is a cru-
cial proangiogenic molecular event [9,10]. We furthermore speculate
that the angiopoietin 2–neutralizing properties of sTie2 may also be
important for MPE suppression and that angiopoietin 2 is part of
the complex mechanism that promotes MPE for the following reasons:
1) Excess amounts of angiopoietin 2 but not angiopoietin 1 are found
in the pleural fluid of patients with MPE [16]. 2) Locally upregulated
angiopoietin 2 is required to initiate tumor-associated angiogenesis
[10]. 3) The attenuation of pleural vascular permeability in animals
treated with the compound and the reduction of the permeability po-
tential of MPE fluid conferred by sTie2 (skin Miles assay) should be
most likely attributed to angiopoietin 2 blockade because angiopoietin
2, but not other members of the angiopoietin family, has permeability-
promoting properties [15]. In contrast, both angiopoietins 1 and 4 have
been shown to inhibit vascular leakage [25,37,38]. 4) sTie2 suppressed
experimental ocular angiogenesis, a process that, similar with the forma-
tion of MPE, is characterized by angiopoietin 2 overexpression [23].
However, we would like to emphasize that, whatever the exact mecha-
nisms, our observations illustrate the importance of the angiopoietin/
Tie2 axis in MPE pathogenesis and suggest that blockade of the path-
way effectively suppresses pleural fluid accumulation and intrapleural
tumor dissemination.
Although this study is the first to report on the effect of angiopoietin/
Tie2 axis blockade in MPE progression, similar interventions have been
previously shown to downregulate angiogenesis and halt tumor growth
in other models of malignant disease [39–42], as well as benign con-
ditions characterized by neovascularization [23,24]. However, in most
of the above studies, the inhibitor was administered with intratumoral
injections [39,40], it was systemically overexpressed through the use
of intravenously injected adenoviruses [24,42], or it was produced by
stably transfected tumor cells [41]. Systemic administration of the in-
hibitor has been only used to suppress retinal neovascularization in
mice [23]. Hence, our study is the first to demonstrate that intermittent
systemic administration of sTie2 is effective against tumor-associated
angiogenesis and can halt cancer growth. Because our treatment proto-
col is more clinically relevant than the above-mentioned inhibition tech-
niques, we suggest that our findings pave the road for clinical studies
using angiopoietin/Tie2 signaling blockade to treat MPE.
In conclusion, the findings reported here indicate that angiopoietin/
Tie2 axis participates in MPE formation, promoting tumor angio-
genesis, tumor-associated pleural inflammation, local release of VEGF
and IL-6, and enhanced pleural vascular permeability. Our results war-
rant further research to explore the role of individual angiopoietins
and probably to define the clinical efficacy and safety of targeting
angiopoietin/Tie2 signaling to treat patients with MPE.
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